Versifel CVR -Wirus panleukopenii kotów (FPV) nie mniej niż 10^3,0 TCID50 i nie więcej niż 10^5,2 TCID50-Herpeswirus kotów typu 1(FVR) nie mniej niż 10^5,0 TCID50 i nie więcej niż 10^7,3 TCID50-Kaliciwirus kotów (FCV) nie mniej niż 10^5,5 TCID50 i nie więcej niż 10^7,5 TCID50 Liofilizat i rozpuszczalnik do sporządzania zawiesiny do wstrzykiwań

Authorised

- Feline panleucopenia virus, Live
- Felid herpesvirus 1, Live
- Feline calicivirus, Live

Product identification

Medicine name:
Versifel CVR -Wirus panleukopenii kotów (FPV) nie mniej niż 10^3,0 TCID50 i nie więcej niż 10^5,2 TCID50-Herpeswirus kotów typu 1(FVR) nie mniej niż 10^5,0

TCID50 i nie więcej niż 10^7,3 TCID50-Kaliciwirus kotów (FCV) nie mniej niż 10^5,5 TCID50 i nie więcej niż 10^7,5 TCID50 Liofilizat i rozpuszczalnik do sporządzania zawiesiny do wstrzykiwań

Active substance:
Feline panleucopenia virus, Live

Felid herpesvirus 1, Live

Feline calicivirus, Live

Target species:
Cat

Route of administration:
Intramuscular use
Subcutaneous use

Product details

Active substance and strength:
Feline panleucopenia virus, Live
158489.00 tissue culture infective dose 50 / 1.00 millilitre(s)

Felid herpesvirus 1, Live
19952600.00 tissue culture infective dose 50 / 1.00 millilitre(s)

Feline calicivirus, Live
31622800.00 tissue culture infective dose 50 / 1.00 millilitre(s)

Pharmaceutical form:
Lyophilisate for suspension for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Cat**

Subcutaneous use:

- **Cat**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI06AD02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Poland

Package description:
Available only in Polish
Available only in Polish
Available only in Polish
Available only in Polish
Available only in Polish
Available only in Polish

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Informed consent application (Article 13c of Directive No 2001/82/EC)

Marketing authorisation holder:
Zoetis Polska Sp. z o.o.

Marketing authorisation date:
1/04/2010

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:
Office For Registration Of Medicinal Products Medical Devices And Biocidal Products

Authorisation number:
1962

Date of authorisation status change:
1/04/2010

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
